Beacon Pointe Advisors, LLC Aquestive Therapeutics, Inc. Transaction History
Beacon Pointe Advisors, LLC
- $8.76 Billion
- Q1 2025
A detailed history of Beacon Pointe Advisors, LLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 60,000 shares of AQST stock, worth $236,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,000
Previous 60,000
-0.0%
Holding current value
$236,400
Previous $212,000
17.92%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AQST
# of Institutions
131Shares Held
44.7MCall Options Held
44.6KPut Options Held
182K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$38.7 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$21.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.07MShares$16 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.73MShares$14.7 Million0.45% of portfolio
-
Geode Capital Management, LLC Boston, MA1.7MShares$6.7 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $210M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...